Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Syndax Pharmaceuticals, Inc. (1T3.F)

11.50
+0.30
+(2.68%)
As of 8:02:13 AM GMT+2. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
23,680
23,680
--
--
139,709
Cost of Revenue
826
826
--
--
--
Gross Profit
22,854
22,854
--
--
--
Operating Expense
362,526
362,526
229,954
151,757
113,489
Operating Income
-339,672
-339,672
-229,954
-151,757
26,220
Net Non Operating Interest Income Expense
21,161
21,161
20,955
2,735
-1,496
Other Income Expense
-247
-247
-361
-316
202
Pretax Income
-318,758
-318,758
-209,360
-149,338
24,926
Net Income Common Stockholders
-318,758
-318,758
-209,360
-149,338
24,926
Diluted NI Available to Com Stockholders
-318,758
-318,758
-209,360
-149,338
24,926
Basic EPS
-3.72
-3.72
-2.98
-2.46
0.48
Diluted EPS
-3.72
-3.72
-2.98
-2.46
0.48
Basic Average Shares
85,622.07
85,622.07
70,370.52
60,760.91
52,064.81
Diluted Average Shares
85,622.07
85,622.07
70,370.52
60,760.91
52,064.81
Total Operating Income as Reported
-339,672
-339,672
-229,954
-151,757
26,220
Total Expenses
363,352
363,352
229,954
151,757
113,489
Net Income from Continuing & Discontinued Operation
-318,758
-318,758
-209,360
-149,338
24,926
Normalized Income
-318,758
-318,758
-209,360
-149,338
24,926
Interest Income
26,090
26,090
21,163
5,872
403
Interest Expense
4,929
4,929
208
3,137
1,899
Net Interest Income
21,161
21,161
20,955
2,735
-1,496
EBIT
-313,829
-313,829
-209,152
-146,201
26,825
EBITDA
-313,821
-313,821
-209,140
-146,168
26,868
Reconciled Cost of Revenue
826
826
--
--
--
Reconciled Depreciation
8
8
12
33
43
Net Income from Continuing Operation Net Minority Interest
-318,758
-318,758
-209,360
-149,338
24,926
Normalized EBITDA
-313,821
-313,821
-209,140
-146,168
26,868
12/31/2021 - 3/11/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AVU0.F Adverum Biotechnologies, Inc.
2.5800
+4.88%
 
1JK.F Apellis Pharmaceuticals, Inc.
14.78
-6.43%
 
69C.MU Tvardi Therapeutics Inc. R
16.62
-1.54%
 
F6T.F Fate Therapeutics, Inc.
1.1715
+2.14%
 
SION Sionna Therapeutics, Inc.
12.60
-3.74%
 
LYEL Lyell Immunopharma, Inc.
0.4670
-2.30%
 
THRD Third Harmonic Bio, Inc.
5.14
-0.19%
 
TENX Tenax Therapeutics, Inc.
5.77
+5.68%
 
TRVI Trevi Therapeutics, Inc.
6.35
+1.28%
 
FULC Fulcrum Therapeutics, Inc.
3.5100
-2.23%